Focusrite Plc (TUNE)
London Exchange · UK · prices in GBX · close of 19 Oct 2026
Key indicators
| Last close | GBX 235.00 |
|---|---|
| 52-week range | 152.02 – 283.95 |
| Return, 1 month / 3 months | −8.7% / −6.0% |
| Return, 1 year / 3 years | +30.9% / −43.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 51 |
| Volatility (1 year) | 51.8% |
| Worst drawdown (1 year) | -37.0% |
| Average daily value traded | 33.80M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Focusrite Plc designs and sells audio recording equipment for musicians, producers and studios. Its products include audio interfaces, microphone preamplifiers, synthesizers, MIDI controllers, studio monitors and loudspeakers, sold under brands such as Focusrite, Novation, ADAM Audio and Martin Audio. Customers range from home recording enthusiasts to professional studios and live sound companies. The company is based in the United Kingdom and sells its equipment in markets around the world.
The shares are listed on the London Exchange in UK under the code TUNE, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Focusrite Plc (TUNE) trades on the London Exchange in UK. It last closed at GBX 235.00 on 19 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 1,386 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 30.9% and over the last three months it fell 6.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.9% | ||
| From 52-week high | -16.1% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.0% | ||
| 6-month return | 26.1% | ||
| 12-month return, skipping the last month | 43.4% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 51.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.0% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 33.80M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 49 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +9.3% |
|---|---|
| 1 month | −8.7% |
| 3 months | −6.0% |
| 6 months | +26.1% |
| 1 year | +30.9% |
| 3 years | −43.7% |
| 5 years | −81.7% |
Signals
| 50-day / 200-day average | 251.73 / 219.91 |
|---|---|
| Golden / death cross (60 days) | Golden, 57 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 10.80 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jul 2026 | GBP 0.0464 |
| 27 Nov 2025 | GBP 0.0210 |
| 8 May 2025 | GBP 0.0210 |
| 24 Dec 2024 | GBP 0.0450 |
| 9 May 2024 | GBP 0.0210 |
| 28 Dec 2023 | GBP 0.0450 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.